These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 28374321)
21. [Benefit of intensity modulated and image-guided radiotherapy in prostate cancer]. Latorzeff I; Mazurier J; Boutry C; Dudouet P; Richaud P; de Crevoisier R Cancer Radiother; 2010 Oct; 14(6-7):479-87. PubMed ID: 20797889 [TBL] [Abstract][Full Text] [Related]
22. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526 [TBL] [Abstract][Full Text] [Related]
23. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy. Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799 [TBL] [Abstract][Full Text] [Related]
24. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471 [TBL] [Abstract][Full Text] [Related]
25. Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer. Ghanem AI; Elsaid AA; Elshaikh MA; Khedr GA Asian Pac J Cancer Prev; 2021 Jan; 22(1):61-68. PubMed ID: 33507680 [TBL] [Abstract][Full Text] [Related]
26. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Napieralska A; Majewski W; Kulik R; Głowacki G; Miszczyk L Radiat Oncol; 2018 Nov; 13(1):235. PubMed ID: 30482212 [TBL] [Abstract][Full Text] [Related]
27. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855 [TBL] [Abstract][Full Text] [Related]
28. Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy. Byrne K; Hruby G; Kneebone A; Whalley D; Guo L; McCloud P; Eade T Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):617-625. PubMed ID: 28416260 [TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770 [TBL] [Abstract][Full Text] [Related]
30. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271 [TBL] [Abstract][Full Text] [Related]
31. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Krenkel B; Eble MJ Strahlenther Onkol; 2011 Aug; 187(8):479-84. PubMed ID: 21789739 [TBL] [Abstract][Full Text] [Related]
32. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807 [TBL] [Abstract][Full Text] [Related]
33. Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy? Eminowicz G; Dean C; Shoffren O; Macdougall N; Wells P; Muirhead R Br J Radiol; 2014 May; 87(1037):20130696. PubMed ID: 24646126 [TBL] [Abstract][Full Text] [Related]
34. Image guided dose escalated prostate radiotherapy: still room to improve. Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007 [TBL] [Abstract][Full Text] [Related]
35. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Luxton G; Hancock SL; Boyer AL Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924 [TBL] [Abstract][Full Text] [Related]
36. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717 [TBL] [Abstract][Full Text] [Related]
37. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Lee CT; Dong L; Ahamad AW; Choi H; Cheung R; Lee AK; Horne DF; Breaux AJ; Kuban DA Am J Clin Oncol; 2005 Dec; 28(6):618-25. PubMed ID: 16317275 [TBL] [Abstract][Full Text] [Related]
38. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069 [TBL] [Abstract][Full Text] [Related]
39. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129 [TBL] [Abstract][Full Text] [Related]
40. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]